Losartan Market Report 2026

Losartan Market Overview

• Losartan market size has reached to $1.49 billion in 2025 • Expected to grow to $1.83 billion in 2030 at a compound annual growth rate (CAGR) of 4.3% • Growth Driver: Growing Prevalence Of Hypertension Fueling The Growth Of The Market Due To Increasing Health Risks And Rising Death Rates • Market Trend: Advancements In Losartan Formulations For Enhanced Patient Convenience And Therapeutic Outcomes • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Losartan Market?

Losartan is an angiotensin II receptor blocker (ARB) commonly used to treat high blood pressure and reduce the risk of stroke in patients with hypertension. It works by relaxing blood vessels, making it easier for the heart to pump blood. Losartan lowers blood pressure, improves heart function, and protects kidney health, especially in patients with diabetes. The main types of losartan dosage are tablet, powder, and suspension. Losartan tablets are convenient, once-daily oral medications used to manage hypertension and diabetic nephropathy. It is sourced from different sources, such as contract manufacturing organizations and in-house, and is distributed through several distribution channels, including online and offline. It is applicable in various applications such as hypertension, stroke, diabetic nephropathy, and others, and is used by various end-users, including adults and pediatrics.

What Is The Losartan Market Growth Forecast?

The losartan market size is expected to see steady growth in the next few years. It will grow to $1.83 billion in 2030 at a compound annual growth rate (CAGR) of 4.3%. The growth in the forecast period can be attributed to aging population growth, rising demand for kidney-protective antihypertensive drugs, expanding access to affordable generics, increasing focus on stroke prevention, higher healthcare spending on chronic disease treatment. Major trends in the forecast period include rising prevalence of hypertension and cardiovascular disorders, growing preference for arbs over ace inhibitors, expansion of generic losartan prescriptions, increasing use in diabetic nephropathy management, rising long-term blood pressure control therapy adoption.

Global Losartan Market Segmentation

1) By Dosage: Tablet, Powder, Suspension 2) By Source: Contract Manufacturing Organizations, In-House 3) By Distribution Channel: Online, Offline 4) By Application: Hypertension, Stroke, Diabetic Nephropathy, Other Applications 5) By End-User: Adult, Pediatric Subsegments: 1) By Tablet: 25 Milligrams (mg), 50 Milligrams (mg), 100 Milligrams (mg) 2) By Powder: 25 Milligrams (mg), 50 Milligrams (mg), 100 Milligrams (mg) 3) By Suspension: 5 Milligrams (mg) Per 5 Milliliters (mL), 10 Milligrams (mg) Per 5 Milliliters (mL), 25 Milligrams (mg) Per 5 Milliliters (mL)

What Is The Driver Of The Losartan Market?

The growing prevalence of hypertension is expected to propel the growth of the losartan market going forward. Hypertension is a condition marked by persistently high blood pressure, which can raise the likelihood of heart disease, stroke, and other severe health complications. The growing incidence of hypertension is linked to diets rich in salt and processed foods, which lead to fluid retention and increased heart strain. Losartan helps control hypertension by blocking angiotensin II, a hormone that narrows blood vessels. This helps relax and widen the vessels, lowering blood pressure and easing the heart's workload. For instance, in January 2025, according to the Centers for Disease Control and Prevention, a US-based organisation, in 2023, high blood pressure played a primary or contributing role in 664,470 deaths in the United States. Therefore, the growing prevalence of hypertension is driving the growth of the losartan industry.

Key Players In The Global Losartan Market

Major companies operating in the losartan market are Viatris Inc., Teva Pharmaceutical Industries Ltd, Intas Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd., Apotex Inc., Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Cadila Pharmaceuticals Ltd., Lupin Ltd., Zydus Lifesciences Ltd., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Vasudha Pharma Chem Ltd., Unichem Laboratories Ltd., Global Pharma Tek, Manus Aktteva Biopharma LLP, Emcure Pharmaceuticals Ltd., Wellona Pharma, JPM Pharma & Chemicals Pvt. Ltd.

Global Losartan Market Trends and Insights

Major companies operating in the losartan market are focusing on developing innovative products and getting approvals, such as losartan potassium oral suspension, to enhance patient compliance and expand therapeutic applications. Losartan potassium oral suspension is a liquid form of medication losartan potassium, intended for individuals who struggle with swallowing tablets. For instance, in March 2025, Scienture Holdings Inc., a US-based biopharmaceutical company, received Food and Drug Administration (FDA) approval for Arbli. It is a ready-to-use liquid formulation for hypertension, stroke risk reduction in hypertensive patients with left ventricular hypertrophy, and diabetic nephropathy in type 2 diabetes patients. It offers precise dosing without compounding and is available in a 165 mL peppermint-flavored suspension (10 mg/mL) with an 18-month shelf life at room temperature.

What Are Latest Mergers And Acquisitions In The Losartan Market?

In April 2025, Scienture Holdings, Inc., a US-based manufacturer of losartan, partnered with Saptalis Pharmaceuticals to manufacture Arbli, a losartan potassium oral suspension (10 mg/mL). The collaboration includes warehousing and distribution agreements with strategic partners to ensure market readiness for the first FDA-approved ready-to-use oral liquid losartan, addressing unmet needs in hypertension treatment. Saptalis Pharmaceuticals is a US-based pharmaceutical company.

Regional Outlook

North America was the largest region in the losartan market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Losartan Market?

The losartan market consists of sales of losartan potassium tablets, losartan-hydrochlorothiazide combination tablets, and generic formulations. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Losartan Market Report 2026?

The losartan market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the losartan industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.